Login
Evidence Feed
About
Diagnostics
New
Top genes
FAQ
Contact us
^
Login
Contact us
to learn more about
our Premium Content: News alerts, weekly reports and conference planners
DRUG CLASS:
RET inhibitor
DRUG CLASS:
RET inhibitor
Contact us
to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Related drugs:
‹
lenvatinib (90)
selpercatinib (67)
pralsetinib (49)
TAS0953/HM06 (7)
AST-487 (5)
RXDX-105 (5)
EP0031 (4)
FHND5071 (4)
BOS-172738 (3)
HG-6-63-01 (2)
SY-5007 (2)
TY-1091 (2)
XMD15-44 (2)
TPX-0046 (2)
HSL468 (1)
HSL476 (1)
HSN608 (1)
LDD-2633 (1)
PLD-102 (1)
APS03118 (0)
BTG-002814 (0)
HS-10365 (0)
HS269 (0)
JNJ-26483327 (0)
LOXO-260 (0)
PLD-101 (0)
SYHA1815 (0)
SKI-G-801 (0)
lenvatinib (90)
selpercatinib (67)
pralsetinib (49)
TAS0953/HM06 (7)
AST-487 (5)
RXDX-105 (5)
EP0031 (4)
FHND5071 (4)
BOS-172738 (3)
HG-6-63-01 (2)
SY-5007 (2)
TY-1091 (2)
XMD15-44 (2)
TPX-0046 (2)
HSL468 (1)
HSL476 (1)
HSN608 (1)
LDD-2633 (1)
PLD-102 (1)
APS03118 (0)
BTG-002814 (0)
HS-10365 (0)
HS269 (0)
JNJ-26483327 (0)
LOXO-260 (0)
PLD-101 (0)
SYHA1815 (0)
SKI-G-801 (0)
›
Associations
(253)
News
Trials
VERI cancer hierarchy
Reset Filters
RET mutation
Thyroid Gland Medullary Carcinoma
RET mutation
Thyroid Gland Medullary Carcinoma
selpercatinib
Sensitive: A1 - Approval
FDA - 2 weeks (New A1)
selpercatinib
Sensitive
:
A1
FDA - 2wk
selpercatinib
Sensitive: A1 - Approval
FDA - 2 weeks
selpercatinib
Sensitive
:
A1
FDA - 2 weeks - (New A1)
RET fusion
Non Small Cell Lung Cancer
RET fusion
Non Small Cell Lung Cancer
pralsetinib
Sensitive: A1 - Approval
pralsetinib
Sensitive
:
A1
pralsetinib
Sensitive: A1 - Approval
pralsetinib
Sensitive
:
A1
RET fusion
Non Small Cell Lung Cancer
RET fusion
Non Small Cell Lung Cancer
selpercatinib
Sensitive: A1 - Approval
selpercatinib
Sensitive
:
A1
selpercatinib
Sensitive: A1 - Approval
selpercatinib
Sensitive
:
A1
RET fusion
Thyroid Gland Carcinoma
RET fusion
Thyroid Gland Carcinoma
pralsetinib
Sensitive: A1 - Approval
pralsetinib
Sensitive
:
A1
pralsetinib
Sensitive: A1 - Approval
pralsetinib
Sensitive
:
A1
RET fusion
Thyroid Gland Carcinoma
RET fusion
Thyroid Gland Carcinoma
selpercatinib
Sensitive: A1 - Approval
selpercatinib
Sensitive
:
A1
selpercatinib
Sensitive: A1 - Approval
selpercatinib
Sensitive
:
A1
No biomarker
Thymic Carcinoma
No biomarker
Thymic Carcinoma
lenvatinib
Sensitive: A1 - Approval
lenvatinib
Sensitive
:
A1
lenvatinib
Sensitive: A1 - Approval
lenvatinib
Sensitive
:
A1
No biomarker
Thyroid Gland Follicular Carcinoma
No biomarker
Thyroid Gland Follicular Carcinoma
lenvatinib
Sensitive: A1 - Approval
lenvatinib
Sensitive
:
A1
lenvatinib
Sensitive: A1 - Approval
lenvatinib
Sensitive
:
A1
No biomarker
Thyroid Gland Hurthle Cell Carcinoma
No biomarker
Thyroid Gland Hurthle Cell Carcinoma
lenvatinib
Sensitive: A1 - Approval
lenvatinib
Sensitive
:
A1
lenvatinib
Sensitive: A1 - Approval
lenvatinib
Sensitive
:
A1
No biomarker
Thyroid Gland Papillary Carcinoma
No biomarker
Thyroid Gland Papillary Carcinoma
lenvatinib
Sensitive: A1 - Approval
lenvatinib
Sensitive
:
A1
lenvatinib
Sensitive: A1 - Approval
lenvatinib
Sensitive
:
A1
No biomarker
Endometrial Cancer
No biomarker
Endometrial Cancer
pembrolizumab + lenvatinib
Sensitive: A1 - Approval
pembrolizumab + lenvatinib
Sensitive
:
A1
pembrolizumab + lenvatinib
Sensitive: A1 - Approval
pembrolizumab + lenvatinib
Sensitive
:
A1
No biomarker
Renal Cell Carcinoma
No biomarker
Renal Cell Carcinoma
everolimus + lenvatinib
Sensitive: A1 - Approval
everolimus + lenvatinib
Sensitive
:
A1
everolimus + lenvatinib
Sensitive: A1 - Approval
everolimus + lenvatinib
Sensitive
:
A1
RET mutation
Thyroid Gland Medullary Carcinoma
RET mutation
Thyroid Gland Medullary Carcinoma
pralsetinib
Sensitive: A1 - Approval
pralsetinib
Sensitive
:
A1
pralsetinib
Sensitive: A1 - Approval
pralsetinib
Sensitive
:
A1
No biomarker
Thyroid Gland Carcinoma
No biomarker
Thyroid Gland Carcinoma
lenvatinib
Sensitive: A1 - Approval
lenvatinib
Sensitive
:
A1
lenvatinib
Sensitive: A1 - Approval
lenvatinib
Sensitive
:
A1
No biomarker
Hepatocellular Cancer
No biomarker
Hepatocellular Cancer
lenvatinib
Sensitive: A1 - Approval
lenvatinib
Sensitive
:
A1
lenvatinib
Sensitive: A1 - Approval
lenvatinib
Sensitive
:
A1
No biomarker
Renal Cell Carcinoma
No biomarker
Renal Cell Carcinoma
pembrolizumab + lenvatinib
Sensitive: A1 - Approval
pembrolizumab + lenvatinib
Sensitive
:
A1
pembrolizumab + lenvatinib
Sensitive: A1 - Approval
pembrolizumab + lenvatinib
Sensitive
:
A1
RET fusion
Solid Tumor
RET fusion
Solid Tumor
selpercatinib
Sensitive: A1 - Approval
selpercatinib
Sensitive
:
A1
selpercatinib
Sensitive: A1 - Approval
selpercatinib
Sensitive
:
A1
MSI-H/dMMR
Endometrial Cancer
MSI-H/dMMR
Endometrial Cancer
pembrolizumab + lenvatinib
Sensitive: A2 - Guideline
pembrolizumab + lenvatinib
Sensitive
:
A2
pembrolizumab + lenvatinib
Sensitive: A2 - Guideline
pembrolizumab + lenvatinib
Sensitive
:
A2
RET fusion
Thyroid Gland Hurthle Cell Carcinoma
RET fusion
Thyroid Gland Hurthle Cell Carcinoma
selpercatinib
Sensitive: A2 - Guideline
selpercatinib
Sensitive
:
A2
selpercatinib
Sensitive: A2 - Guideline
selpercatinib
Sensitive
:
A2
RET fusion
Thyroid Gland Follicular Carcinoma
RET fusion
Thyroid Gland Follicular Carcinoma
selpercatinib
Sensitive: A2 - Guideline
selpercatinib
Sensitive
:
A2
selpercatinib
Sensitive: A2 - Guideline
selpercatinib
Sensitive
:
A2
RET fusion
Thyroid Gland Papillary Carcinoma
RET fusion
Thyroid Gland Papillary Carcinoma
selpercatinib
Sensitive: A2 - Guideline
selpercatinib
Sensitive
:
A2
selpercatinib
Sensitive: A2 - Guideline
selpercatinib
Sensitive
:
A2
RET rearrangement
Non Small Cell Lung Cancer
RET rearrangement
Non Small Cell Lung Cancer
selpercatinib
Sensitive: A2 - Guideline
selpercatinib
Sensitive
:
A2
selpercatinib
Sensitive: A2 - Guideline
selpercatinib
Sensitive
:
A2
RET rearrangement
Non Small Cell Lung Cancer
RET rearrangement
Non Small Cell Lung Cancer
pralsetinib
Sensitive: A2 - Guideline
pralsetinib
Sensitive
:
A2
pralsetinib
Sensitive: A2 - Guideline
pralsetinib
Sensitive
:
A2
RET mutation
Thyroid Gland Anaplastic Carcinoma
RET mutation
Thyroid Gland Anaplastic Carcinoma
selpercatinib
Sensitive: A2 - Guideline
selpercatinib
Sensitive
:
A2
selpercatinib
Sensitive: A2 - Guideline
selpercatinib
Sensitive
:
A2
RET fusion
Thyroid Gland Papillary Carcinoma
RET fusion
Thyroid Gland Papillary Carcinoma
pralsetinib
Sensitive: A2 - Guideline
pralsetinib
Sensitive
:
A2
pralsetinib
Sensitive: A2 - Guideline
pralsetinib
Sensitive
:
A2
RET fusion
Thyroid Gland Hurthle Cell Carcinoma
RET fusion
Thyroid Gland Hurthle Cell Carcinoma
pralsetinib
Sensitive: A2 - Guideline
pralsetinib
Sensitive
:
A2
pralsetinib
Sensitive: A2 - Guideline
pralsetinib
Sensitive
:
A2
RET fusion
Thyroid Gland Follicular Carcinoma
RET fusion
Thyroid Gland Follicular Carcinoma
pralsetinib
Sensitive: A2 - Guideline
pralsetinib
Sensitive
:
A2
pralsetinib
Sensitive: A2 - Guideline
pralsetinib
Sensitive
:
A2
RET fusion
Thyroid Gland Anaplastic Carcinoma
RET fusion
Thyroid Gland Anaplastic Carcinoma
pralsetinib
Sensitive: A2 - Guideline
pralsetinib
Sensitive
:
A2
pralsetinib
Sensitive: A2 - Guideline
pralsetinib
Sensitive
:
A2
No biomarker
Clear Cell Renal Cell Carcinoma
No biomarker
Clear Cell Renal Cell Carcinoma
lenvatinib
Sensitive: A2 - Guideline
lenvatinib
Sensitive
:
A2
lenvatinib
Sensitive: A2 - Guideline
lenvatinib
Sensitive
:
A2
No biomarker
Biliary Tract Cancer
No biomarker
Biliary Tract Cancer
pembrolizumab + lenvatinib
Sensitive: A2 - Guideline
pembrolizumab + lenvatinib
Sensitive
:
A2
pembrolizumab + lenvatinib
Sensitive: A2 - Guideline
pembrolizumab + lenvatinib
Sensitive
:
A2
RET fusion
Neuroendocrine Tumor
RET fusion
Neuroendocrine Tumor
selpercatinib
Sensitive: A2 - Guideline
selpercatinib
Sensitive
:
A2
selpercatinib
Sensitive: A2 - Guideline
selpercatinib
Sensitive
:
A2
RET fusion
Ovarian Cancer
RET fusion
Ovarian Cancer
selpercatinib
Sensitive: A2 - Guideline
selpercatinib
Sensitive
:
A2
selpercatinib
Sensitive: A2 - Guideline
selpercatinib
Sensitive
:
A2
RET fusion
Salivary Gland Cancer
RET fusion
Salivary Gland Cancer
selpercatinib
Sensitive: A2 - Guideline
selpercatinib
Sensitive
:
A2
selpercatinib
Sensitive: A2 - Guideline
selpercatinib
Sensitive
:
A2
RET fusion
Colon Cancer
RET fusion
Colon Cancer
selpercatinib
Sensitive: A2 - Guideline
selpercatinib
Sensitive
:
A2
selpercatinib
Sensitive: A2 - Guideline
selpercatinib
Sensitive
:
A2
^
^
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login